

8. Kosik P, Durdik M, Skorvaga M, Klimova D. Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples. *Antioxidants* 2021; 10(3), 481.
9. Laguna-Olmos M et al. Leucemia mieloide aguda y pre-eclampsia coexistente. Algunas dificultades diagnósticas. A propósito de un caso. *Revista chilena de obstetricia y ginecologia* 2020; 85(2): 155–161.
10. <https://ghr.nlm.nih.gov/gene/AML1> [cit. 2021-02-18]
11. Krejci O, Wunderlich M, Geiger H. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. *Am. J. Hematol* 2008; 111(4), 2190–2199.
12. Oo Z M, Illendula A, Grembecka J. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBF $\beta$  in leukemic cells. *Leukemia & lymphoma* 2018; 59(9), 2188–2200.
13. Zahedipour F, Ranjbaran R, Behzad A et al. Development of Flow Cytometry-Fluorescent In Situ Hybridization (Flow-FISH) Method for Detection of PML/RAR $\alpha$  Chromosomal Translocation in Acute Promyelocytic Leukemia Cell Line. *Avicenna J. Med. Biotechnol* 2017; 9(2): 104–108.
14. Lallemand-Breitenbach, V. PML nuclear bodies. *Cold Spring Harb Perspect Biol* 2010; 2(5).
15. Matt S, Hofmann T. G. Crosstalk between p53 modifiers at PML bodies. *Molecular & cellular oncology* 2018; 5(3).
16. Wang, G, Tian Y, Hu Q. PML/RAR $\alpha$  blocks the differentiation and promotes the proliferation of acute promyelocytic leukemia through activating MYB expression by transcriptional and epigenetic regulation mechanisms. *J. Cell. Biochem* 2019; 120(2): 1210–1220.
17. Zhu H H, Yang M C, Wang F. Identification of a novel NUP98–RARA fusion transcript as the 14<sup>th</sup> variant of acute promyelocytic leukemia. *Am. J. Hematol* 2020; 95(7): E184–E186.
18. Testi A M, Biondi A, Coco F L et al. Protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. *Blood* 2005; 106(2), 447–453.
19. Soignet S L, Maslak P, Wang Z et al. Complete Remission After Treatment of Acute Promyelocytic. *NEJM* 1998; 339: 1341–1348.
20. Burnett A K, Russell N H, Hills R K. Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. *The Lancet Oncology* 2015; 16(13): 1295–1305.
21. Platzbecker U, Avvisati G, Cicconi L. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. *Am. J. Clin. Oncol* 2017.
22. Bernard O, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. *Genes Chromosomes Cancer* 1995;13: 75–85.
23. Balgobind B V, Raimondi S C, Harbott J et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. *Blood* 2009; 114(12), 2489–2496.
24. Kuntimaddi A, Achille N J, Thorpe J. Degree of recruitment of DOT1L to MLL-AF9 defines level of H3K79 di- and tri-methylation on target genes and transformation potential. *Cell Rep* 2015; 11: 808–820.
25. Rowley JD. The critical role of chromosome translocations in human leukemias. *Annu. Rev. Genet* 1998; 32(1), 495–519.
26. Tonks A, Tonks A J, Pearn L et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. *Leukemia* 2004; 18(7): 1238–1245.
27. <https://ghr.nlm.nih.gov/gene/RARA> [cit. 2021-02-18]
28. Nunes V S, Moretti N S. Nuclear subcompartments: an overview. *Cell biology international* 2016; 41: 2–7.
29. Wood A M, Garza-Gongora AG, Kosak A. A crowdsourced nucleus : understanding nuclear organization in terms of dynamically networked protein function, *BBA* 2014; ISSN 1874-9399.
30. Lang M, Jegou T, Chung I. Three-dimensional organization of promyelocytic leukemia nuclear bodies. *J. Cell. Sci* 2010; 123(3): 392–400.
31. Lausten-Thomsen U, Madsen HO, Vestergaard TR et al. Prevalence of t(12;21)[ETV6-RUNX1]-positive cells in healthy neonates. *Blood* 2011; 117: 186–189.
32. Wayne AS, Baird K, Egeler RM. Hematopoietic stem cell transplantation for leukemia. *Pediatr Clin North Am* 2010; 57: 1–25.
33. Oliansky DM, Rizzo JD, Aplan PD. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. *Biol Blood Marrow Transplant* 2007; 13: 1–25.
34. Rosenthal J, Woolfrey AE, Pawlowska A et al. Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. *Pediatr Blood Cancer* 2011.
35. Ballen K K, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private? *Bone Marrow Transplant* 2015; 50: 1271–1278.

## Rádi vám pomáhamo v on-line vzdelávaní

23

on-line kurzů a kongresů

160

přednášek

1340

vydaných certifikátů

7200

účastníků

